Olumniant (Baricitinib) oral tablets: An insight into FDA-approved systemic treatment for Alopecia Areata

Eman Ali, Rabia Owais, Ayesha Sheikh, Asim Shaikh

Annals of Medicine and Surgery · 2022 · 30 citations · 4 references

DOIFull text

Open access

Concepts

Abstract

Olumniant (Barcitinib) has gained swift approval by the Food and Drug Administration (FDA) as a promising medication for the treatment of adults with severe Alopecia Areata. This drug has proven to be effective for various conditions including Covid-19 and Rheumatoid Arthritis as well as being found to be less costly and minimally invasive, with no need for post-operative management. However, its use has some considerable potential implications before its prescription can be made commonplace. Therefore, more trials need to be conducted to establish a more rigid safety profile.

References

4